IL23A and psoriasis: LCN-2 has recently been proposed as a potential target for psoriasis treatment, since it is involved in keratinocyte differentiation and pathogenesis of psoriasis by stimulating neutrophil function, Th17 activation, and secretion of IL-23 by dendritic cells [11].